| 39.30 Data as of Jun 19 |  -0.34 / -0.86%Today’s Change | 36.63 Today|||52-Week Range 42.83 | +5.25% Year-to-Date |
| SECTOR Health Technology | INDUSTRY Pharmaceuticals: Generic | MARKET CAP $37.4B |
Company Description
Teva Pharmaceutical Industries Ltd. is engaged in the provision of pharmaceutical services. It operates through the following business divisions: Generic, Branded, and Over-the-Counter (OTC). The Generic division involves the manufacture and sale of generic products such as tablets, capsules, ointments, creams, liquids, injectables, and inhalants. The Branded division provides products for central nervous system (CNS), respiratory system, women's health, oncology, and others. The OTC division offers medicines in categories such as cough and cold, allergy, digestive wellness, vitamins, minerals and supplements, analgesics, and skin medications. Its products are manufactured under the Copaxone, Provigil, Azilect, Nuvigil, ProAir, Qvar, Treanda, Lonquex, Revascor, Milprosa, LeCette, Quartette, NexoBrid, and StemEx brand names. The company was founded in 1901 and is headquartered in Petach Tikva, Israel.
Employees
Shareholders
| Other institutional | 29.38% |
| Mutual fund holders | 21.83% |
| Individual stakeholders | -- |
Top Executives
| Jeremy M. Levin, PhD | President & Chief Executive Officer |
| Carlo de Notaristefani, PhD | President & CEO-Global Operations |
| Eyal Desheh, MBA | CFO & Group Executive Vice President |
| Michael R. Hayden, MD, PhD | President-Global Research & Development |
| Richard S. Egosi, MBA | Company Secretary, Chief Legal Officer & EVP |
.
